OncoSec Medical (OTC:ONCS) has been featured in the magazine Medical Device & Diagnostic Industry, the company said Wednesday.
The biomedical company, founded in 2011, develops advance-stage
ElectroOncology anti-cancer therapies to treat people with solid
The March article titled “OncoSec Could Revolutionize Oncology
Therapy” details the company’s promising OMS ElectroOncology treatment
platform. The article can be accessed here: http://www.mddionline.com/article/oncoSec-could-revolutionize-oncology-therapy
The magazine noted OncoSec’s on-going Phase II clinical studies in
metastatic melanoma and Merkel cell carcinoma, a rare and aggressive
The article also notes the company’s upcoming milestones for this year.
The magazine is published monthly and written expressly for original
equipment manufacturers of medical devices and in vitro diagnostic
It has a circulation of about 50,500, and its goal is to aide
industry professionals in the design, and development of medical
products that comply with regulations and market requirements.
On Tuesday, OncoSec announced that it dosed its first patient in a
Phase II clinical trial testing its OMS ElectroImmunotherapy treatment
on advanced-stage metastatic melanoma patients.
The dosing comes as the University of California San Francisco (UCSF)
received approval from the Investigational Review Board for the trial.
UCSF investigators are currently recruiting for this clinical trial.
OncoSec uses its electroporation delivery system which applies cell
membrane stimulation to deliver immunotherapy or chemotherapy to treat a
range of cancerous tumour types.
The OMS electroporation system has proven to enhance cellular uptake,
effectively treating cancerous cells while sparing surrounding healthy
tissue – cutting through the toxic side effects of current available
treatment options like chemotherapy and radiation.
In 2011, the company managed to outline a clinical development plan
for its local and potentially systemic ElectroImmunotherapy program,
which uses the OncoSec Medical System (OMS) to deliver a DNA-based
immunotherapy, known as DNA IL-12, designed to induce a local immune
response against the treated cancerous tumor, while exploiting this
response to initiate a global systemic response against untreated tumors
in other areas of the body.
For the metastatic melanoma trial, a total of up to 25 patients with
stage three or four cutaneous and in-transit metastatic melanoma will be
enrolled in the phase two, single-arm, open-label and multi-centre